12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder [clinicaltrials:NCT00004058]
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder [clinicaltrials:NCT00004058]
Bio2RDF identifier
NCT00004058
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00004058
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... ponded to previous treatment.
brief title [clinicaltrials_vocabulary:brief-title]
12-O-Tetradecanoylphorbol-13-a ...... Cancer or Bone Marrow Disorder
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2004-11-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... ll be accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-12-10T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
T-cell large granular lymphocyte leukemia
Waldenstrom macroglobulinemia
acute undifferentiated leukemia
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-01-25T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00004058
official title [clinicaltrials_vocabulary:official-title]
Phase I Study of 12-O-tetradec ...... gnancies/Bone Marrow Disorders
org study id [clinicaltrials_vocabulary:org-study-id]
5986; CDR0000067255
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-11-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
P30CA072720
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1998-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2010-01-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
At this time it is felt that w ...... n from an additional patients.
identifier
clinicaltrials:NCT00004058
title
12-O-Tetradecanoylphorbol-13-a ...... Cancer or Bone Marrow Disorder
@en
type
label
12-O-Tetradecanoylphorbol-13-a ...... r [clinicaltrials:NCT00004058]
@en